Your session is about to expire
← Back to Search
GS-0272 for Rheumatoid Arthritis and Lupus (MARASLE Trial)
MARASLE Trial Summary
This trial looks at the safety & tolerability of a drug (GS-0272) for RA & SLE patients, & how it affects their bodies.
MARASLE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMARASLE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.MARASLE Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has GS-0272 been formally sanctioned by the Federal Drug Administration?
"There is limited clinical evidence for the safety and efficacy of GS-0272, so it gets a score of 1."
Is this research initiative open to adults of a certain age and older?
"Those eager to join this clinical trial must fall between the ages of 18 and 75. Meanwhile, there are 78 studies for minors under 18 years old and 463 trials designed specifically for seniors over 65."
Is there an ongoing recruitment for participants in this research trial?
"As per clinicaltrials.gov, this medical trial is actively seeking participants - it was first made available on September 28th 2023 and last modified on October 9th of the same year."
How many participants are enrolled in the current clinical trial?
"Affirmative. According to the data available on clinicaltrials.gov, this medical trial has been open since September 28th 2023 and is still seeking volunteers for participation. The research team requires 48 participants from a single site."
Is it possible for me to join this medical research?
"This clinical trial is recruiting 48 participants aged 18-75 who have rheumatoid arthritis. The selection criteria includes adhering to the 2010 American College of Rheumatology/European League Against Rheumatism classification; not being on a biologic or synthetic disease-modifying antirheumatic drug at start date and for 4 weeks (except for rituximab which requires 16 week discontinuation); fulfilling EULAR/ACR 2019 SLE classifications at least 24 weeks prior, and maintaining stable doses of protocol-approved immunosuppressive agents (antimalarials, methotrexate, etc"
Share this study with friends
Copy Link
Messenger